A5074175963- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Glioma Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Peptidase Inhibition and Analysis
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Epigenetics and DNA Methylation
- Cancer Treatment and Pharmacology
- Carcinogens and Genotoxicity Assessment
- Pharmaceutical and Antibiotic Environmental Impacts
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
- Pesticide Exposure and Toxicity
- Renal cell carcinoma treatment
- Histone Deacetylase Inhibitors Research
- Polyamine Metabolism and Applications
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Treatments and Mutations
- Biopolymer Synthesis and Applications
Daiichi-Sankyo (Japan)
2019-2024
Tokyo University of Science
2023
Kyoto University
2019
Kyoto Pharmaceutical University
2005
Abstract Background Approximately 70% of lower-grade gliomas harbor isocitrate dehydrogenase 1 (IDH1) mutations, resulting in the accumulation oncometabolite D-2-hydroxyglutarate (D-2-HG); this leads to epigenetic dysregulation, oncogenesis, and subsequent clonal expansion. DS-1001 is an oral brain-penetrant mutant IDH1 selective inhibitor. This first-in-human study investigated safety, pharmacokinetics, pharmacodynamics, efficacy DS-1001. Methods was a multicenter, open-label,...
Abstract The global phase 3 DESTINY‐Breast03 study ( ClinicalTrials.gov ; NCT03529110) showed statistically significant and clinically meaningful improvements in progression‐free survival (PFS) overall (OS) with trastuzumab deruxtecan (T‐DXd) over emtansine (T‐DM1) patients human epidermal growth factor receptor 2 (HER2)‐positive metastatic breast cancer (mBC) previously treated a taxane. Here, we report subgroup analysis of Asian enrolled DESTINY‐Breast03. In total, 309 (149 the T‐DXd arm...
2004 Background: WHO grade II/III gliomas frequently harbor isocitrate dehydrogenase 1 ( IDH1) mutations, resulting in intratumoral accumulation of oncometabolite 2-hydroxyglutarate (2-HG) and subsequent clonal expansion. DS-1001b is an oral selective inhibitor mutant IDH1 R132X that was designed to penetrate the blood-brain barrier. Methods: In this first-in-human, multicenter, phase I study (NCT03030066), eligible patients (pts) with recurrent/progressive glioma received twice daily (bid),...
Abstract Background In the global phase 3 DESTINY-Breast04 study (NCT03734029), anti-human epidermal growth factor 2 (HER2) antibody–drug conjugate trastuzumab deruxtecan (T-DXd) demonstrated a statistically significant improvement in progression-free survival (PFS) and overall (OS), with manageable safety compared treatment of physician’s choice (TPC) patients HER2-low metastatic breast cancer (mBC) who had received 1–2 prior lines chemotherapy. Methods This subgroup analysis examined...
Aim: This study estimated the incidence of moderate-to-severe drug-induced interstitial lung disease (ILD) among patients with breast cancer in Japan. Methods: We analyzed a large nationwide database treated anticancer therapies between 2009 and 2022. ILD was identified using diagnostic codes treatment records. Results: Of 81,601 patients, 1042 developed requiring corticosteroids, corresponding to an rate 1.41 per 100 person-years. The varied across years regimens. Most incidents occurred...
3-Nitrobenzanthrone (3-NBA) is an extremely potent direct-acting bacterial mutagen that has been detected in diesel exhaust particles, airborne particles and so forth. Recently, 3-aminobenzanthrone (3-ABA) 3-acetylaminobenzanthrone (3-AABA) were identified as metabolites of 3-NBA mammalian cells. In this study, to clarify the genotoxicity 3-ABA, 3-AABA vitro vivo, mutagenicity DNA-damaging activity these chemicals investigated by Ames assay alkaline single gel electrophoresis (Comet assay),...
Abstract BACKGROUND WHO grade II/III gliomas frequently harbor isocitrate dehydrogenase 1 (IDH1) mutations, resulting in intratumoral accumulation of oncometabolite D-2-hydroxyglutarate (D-2-HG) and subsequent clonal expansion. DS-1001b is an oral selective inhibitor mutant IDH1 R132X that was designed to penetrate the blood-brain barrier. METHODS In this first-in-human, multicenter, phase I study (NCT03030066), eligible patients (pts) with recurrent/progressive glioma received twice daily...